"Up there - once again - with the big boys."
Methotrexate Sodium is a drug designed to fight cancer and is currently backlogged with no guarantee for fulfillment in the near-term. This comes as Elite recently announced the FDA green-lit their ~~knockoff~~ nay, generic version.
On May 20, 2024, in a press release, Elite Pharmaceuticals, Inc., or Elite, reported that it received approval from the US Food and Drug Administration (FDA) on May 16, 2024 for a generic version of Methotrexate Sodium (“Methotrexate”) 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories, Inc. label.
There's a description of this shortage which includes the [then known] alternatives available:
Available Products
- Methotrexate injection, Fresenius Kabi, 25 mg/mL, 10 mL (with preservative) vial, 1 count, NDC 63323-0123-10
- Methotrexate, Fresenius Kabi, 1 gram, vial, 1 count, NDC 63323-0122-50
- Methotrexate injection, Pfizer, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 61703-0408-41
- Methotrexate injection, Teva, 25 mg/mL, 10 mL preservative-free vial, 1 count, NDC 00703-3675-01
- Methotrexate injection, Teva, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 00703-3678-01
$ELTP's announcement came only days later, but it is up there - once again - with the big boys.
